Clinical trials: Clopidogrel
Kawasaki Disease, Coronary Artery Aneurysm
Rivaroxaban for Children Aged Over 2 Years With Giant Coronary Artery Aneurysms After Kawasaki Disease
Based on population pharmacokinetic model-based simulation, a 15 mg-equivalent, age-, and bodyweight-adjusted dosing regimen for Chinese children with giant coronary artery aneurysms after acute Kawasaki disease was proposed.
- Trial name
- RIVA-KG (NCT05643651)
- Testing
- Rivaroxaban Oral Tablet [Xarelto], Aspirin or Clopidogrel, Warfarin
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Children's Hospital of Fudan University
Carotid Artery Diseases, Stroke
Carotid Artery Disease After Stroke (CADAS).
Stroke is a significant medical problem with 150,000 events occurring per year in the UK and incurring healthcare costs of £4 billion per year.
- Conditions
- Carotid Artery Diseases, Stroke, Transient Ischemic Attack
- Trial name
- CADAS (NCT03721523)
- Testing
- 3 Dimensional tomographic Ultrasound, Platelet Aggregometry
- Where
- 3 sites in United Kingdom
- Sponsor
- University of Manchester
Hip Fracture
Hip-Fracture Surgery on Patients in Clopidogrel Therapy
Patients in Clopidogrel therapy alone or in combination with acetylsalicylic acid (Dual Antiplatelet Therapy (DAPT) presenting with a hip-fracture represent the surgeon with the dilemma of putting the patient at risk of a major…
- Trial name
- NCT02391883
- Testing
- Clopidogrel
- Volunteers
- 356 people
- Sponsor
- Hvidovre University Hospital
Renal Failure, Coronary Artery Disease
Effect of Haemodialysis on the Efficacy of Antiplatelet Agents
The main purpose of our study is to investigate whether haemodialysis itself affects the efficacy of antiplatelet drugs and the effects of two different types of dialysis membranes (polysulfone membranes and polyamide membranes)…
- Conditions
- Renal Failure, Coronary Artery Disease, Hemolysis
- Trial name
- NCT03330223
- Testing
- Clopidogrel group;Ticagrelor group
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Coronary Artery Disease, Diabetes Mellitus
Clopidogrel Versus Ticagrelor in Type-2 Diabetes
CLOTILDIA is a single-center, prospective, randomized, open label, cross-over study evaluating the effects of ticagrelor versus high-dose clopidogrel on endothelial function and platelet reactivity in patients with type-2…
- Trial name
- NCT02742987
- Testing
- Ticagrelor, Clopidogrel, Standard medical therapy
- Volunteers
- 42 people
- Sponsor
- Campus Bio-Medico University
Acute Coronary Syndrome, High Bleeding Risk
LEADERS FREE II: BioFreedom™ Pivotal Study
This study aims to confirm non-inferiority of the BioFreedom™ Drug Coated Stent to the Gazelle™ Bare Metal Stent arm of the Leaders Free study (NCT01623180) in high bleeding risk patients.
- Trial name
- NCT02843633
- Testing
- BioFreedom™ Drug Coated Coronary Stent System, Antiplatelet Drug
- Where
- 66 sites in United States, Canada and 5 more
- Volunteers
- 1,203 people
- Sponsor
- Biosensors Europe SA
Transient Ischemic Attacks, Minor Stroke
The Middle East Dual Anti-platelet Treatment in Acute Transient Ischemic Attack
The primary goal of the research is to determine if 10 days of dual anti-platelet treatment is as effective as 30 days of similar treatment in the prevention of stroke, myocardial ischemia (MI) and death in patients with TIAs and…
- Trial name
- MENA-TIA (NCT02144831)
- Testing
- anti-thrombotic treatment using Aspirin (ASA 75-325mg) and Clopidogrel (75mg)
- Where
- Canada
- Sponsor
- University of Alberta
Collateral Circulation, Large-artery Occlusion
Study of Collateral Circulation in Patients With Symptomatic Intracranial Anterior Circulation Occlusion
Intracranial artery stenosis is the leading cause of stroke onset or recurrence in Asian. Multiple studies have shown that anterior circulation is most common in intracranial artery stenosis, especially the middle cerebral artery…
- Conditions
- Collateral Circulation, Large-artery Occlusion, Cerebral Infarction
- Trial name
- NCT04091412
- Testing
- Butylphthalide Soft Capsules
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- The Second Hospital of Hebei Medical University
Venous Thrombosis, Pulmonary Embolism
Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)
This prospective cohort study will provide information about: characteristics of Rivaroxaban use in patients who are prescribed Rivaroxaban for the first time compared to patients who are prescribed Warfarin for the first time…
- Conditions
- Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation, Acute Coronary Syndrome
- Trial name
- NCT01947998
- Testing
- Rivaroxaban (Xarelto, Bay59-7939), Warfarin, Antiplatelet drugs
- Where
- United Kingdom
- Volunteers
- 50,299 people
- Sponsor
- Bayer
Cerebrovascular Disease
Individualized Antithrombotic Therapy for Patients With Ischemic Cerebrovascular Disease
To investigate the therapeutic effect of individualized treatment of antiplatelet in secondary prevention of ischemic stroke.
- Trial name
- NCT03471169
- Testing
- Desirable TEG, Undesirable TEG
- Where
- China
- Volunteers
- 3,500 people, healthy volunteers welcome
- Sponsor
- Xuanwu Hospital, Beijing
Platelet Reactivity
Platelet Function Monitoring in Patients Treated With Clopidogrel at the Time of Primary Percutaneous Coronary Angioplasty
Platelets are a major component of clot formation which can lead to clotting events such as heart attack. During treatment for a heart attack, doctors try to remove this blockage as quickly as possible so that the heart can…
- Trial name
- NCT00827346
- Testing
- Clopidogrel
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- Ottawa Heart Institute Research Corporation
Acute Coronary Syndrome, Venous Thrombosis
Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)
This prospective cohort study will provide information about: Characteristics of Rivaroxaban use in patients who are prescribed Rivaroxaban for the first time compared to patients who are prescribed standard of care for the first…
- Conditions
- Acute Coronary Syndrome, Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation
- Trial name
- NCT02468102
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Standard of care drugs
- Where
- Sweden
- Volunteers
- 99,999 people
- Sponsor
- Bayer
Coronary Artery Disease, Coronary Artery Stenosis
Nationwide Cohort Study of Antiplatelet Agents as Primary Prevention
There is no specific recommendation regarding pharmacologic treatment as primary prevention for patients with intermediate coronary artery stenosis whose revascularization was deferred based on negative fractional flow reserve…
- Trial name
- NHIS (NCT06281041)
- Testing
- Antiplatelet Agents
- Where
- South Korea
- Volunteers
- 4,657 people
- Sponsor
- Samsung Medical Center
Coronary Artery Disease
Resistance on Antithrombotic Drugs in Ischemic Heart Disease
The purpose of this study is to determine whether aspirin and clopidogrel resistance measured with Multiplate function analyser has a good correlation with incidence of major adverse cardiac events in patients with coronary…
- Trial name
- NCT00742430
- Testing
- PCI
- Where
- Croatia
- Volunteers
- 141 people
- Sponsor
- University of Zagreb
Ischemic Stroke, Large-Artery Atherosclerosis (Embolus/Thrombosis)
Study of Predictive Factors Related to Prognosis of Patients With Ischemic Stroke Due to Large-artery Atherosclerosis
This is a single-center prospective cohort study of predictive factors related to prognosis of ischemic stroke due to large-artery atherosclerosis.
- Trial name
- NCT04847752
- Testing
- carotid artery stenting, carotid endarterectomy, Aspirin
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Tongji Hospital
Ischemic Stroke, Patent Foramen Ovale
Patent Foramen Ovale Closure or Anticoagulants Versus Antiplatelet Therapy to Prevent Stroke Recurrence
A patent foramen ovale (PFO) is found more frequently in patients with an ischemic stroke than in control subjects. Therapeutic options to prevent stroke recurrence include antiplatelet drugs, oral anticoagulants, and…
- Conditions
- Ischemic Stroke, Patent Foramen Ovale, Atrial Septal Aneurysm, Migraine
- Trial name
- CLOSE (NCT00562289)
- Testing
- aspirin, Antivitamins K or rivaroxaban or dabigatran or apixaban, Devices for PFO closure
- Where
- France
- Volunteers
- 664 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Venous Thrombosis, Pulmonary Embolism
Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)
This prospective cohort study will provide information about: characteristics of Rivaroxaban use in patients who are prescribed Rivaroxaban for the first time compared to patients who are prescribed Acenocoumarol for the first…
- Conditions
- Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation, Acute Coronary Syndrome
- Trial name
- NCT01947985
- Testing
- Rivaroxoban (Xarelto, Bay59-7939), Standard of care
- Where
- Netherlands
- Volunteers
- 208,958 people
- Sponsor
- Bayer
Coronary Artery Disease
The Optimal Duration of Dual Antiplatelet Therapy After Implantation of Endeavor Stent
The purpose of this study to determine whether the dual antiplatelet therapy (aspirin and clopidogrel) for 3 months after coronary implantation of zotarolimus-eluting stent is safe in terms of death, myocardial infarction, or…
- Trial name
- DATE (NCT00418860)
- Testing
- Aspirin, Clopidogrel
- Where
- South Korea
- Volunteers
- 1,200 people
- Sponsor
- Samsung Medical Center
Congenital Heart Defects, Blood Platelet Disorders
Platelet Aggregation Inhibition in Children on Clopidogrel (PICOLO)
PICOLO is a double blind placebo controlled phase II dose ranging, dose escalating study in patients of Blalock-Taussig age categories (neonates and infants/toddlers), to determine the dose providing inhibition of platelet…
- Trial name
- NCT00115375
- Testing
- Clopidogrel (SR25990)
- Where
- 6 sites in United States, Belgium and 4 more
- Volunteers
- 92 people
- Sponsor
- Sanofi
Peripheral Arterial Disease
Genotype-guided Strategy for Antithrombotic Treatment in Peripheral Arterial Disease.
Rationale: Peripheral arterial disease (PAD) is a common presentation of atherosclerosis. For the prevention of adverse events related to arterial thrombosis in PAD patients, clopidogrel is recommended.
- Trial name
- GENPAD (NCT04619927)
- Testing
- Direct CYP2C19 genotyping, CYP2C19 genotyping at the end of the study, Poor metabolisers
- Where
- 11 sites in Netherlands
- Volunteers
- 2,276 people
- Sponsor
- Radboud University Medical Center